Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B

Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy

(2010) Chau-Ting Yeh   ANTIVIRAL THERAPY

Management of Chronic Hepatitis B with Nucleoside or Nucleotide Analogues: A Review of Current Guidelines

(2010) Moon Seok Choi et al.   Gut and Liver

Clinical outcome of lamivudine-resistant chronic hepatitis B patients with compensated cirrhosis under adefovir salvage treatment.

(2009) I. Elefsiniotis et al.   European Journal of Internal Medicine

Development of HCC in patients receiving adefovir dipivoxil for lamivudine-resistant hepatitis B virus mutants

(2009) Tetsuya Hosaka et al.   HEPATOLOGY RESEARCH

Virological Response and Hepatocarcinogenesis in Lamivudine-Resistant Hepatitis B Virus Genotype C Patients Treated with Lamivudine plus Adefovir Dipivoxil

(2009) Norio Akuta et al.   INTERVIROLOGY

Associations Between Hepatitis B Virus Mutations and the Risk of Hepatocellular Carcinoma: A Meta-Analysis

(2009) Shijian Liu et al.   JNCI-Journal of the National Cancer Institute

The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound

(2008) Nadia Warner et al.   HEPATOLOGY

Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure

(2008) Stéphanie Villet et al.   JOURNAL OF HEPATOLOGY